Hadean Ventures leads Kasvu Therapeutics’ €30 million Series A round

PUBT · 3d ago
Hadean Ventures leads Kasvu Therapeutics’ €30 million Series A round
  • Kasvu Therapeutics raised a EUR 30 million Series A round led by Hadean Ventures to advance its TrkB potentiator program.
  • Kasvu develops small-molecule TrkB positive allosteric modulators designed to boost neuroplasticity without 5-HT2A-driven hallucinogenic effects.
  • Proceeds will fund IND/CTA-enabling work for lead asset KTX-0141 through Phase 1/1b development in major depressive disorder.
  • Clinical development is expected to start in 2H 2027, including an initial controlled efficacy assessment in patients with major depressive disorder.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hadean Ventures AS published the original content used to generate this news brief on September 24, 2026, and is solely responsible for the information contained therein.